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Abstract
Previous studies of the alpha-synuclein null mutant mice on the C57Bl6 genetic background have revealed reduced
number of dopaminergic neurons in their substantia nigra pars compacta (SNpc). However, the presence in
genomes of the studied mouse lines of additional genetic modifications that affect expression of genes located in a
close proximity to the alpha-synuclein-encoding Snca gene makes these data open to various interpretations. To
unambiguously demonstrate that the absence of alpha-synuclein is the primary cause of the observed deficit of
dopaminergic neurons, we employed a recently produced constituent alpha-synuclein knockout mouse line B6(Cg)-
Sncatm1.2Vlb/J. The only modification introduced to the genome of these mice is a substitution of the first coding
exon and adjusted short intronic fragments of the Snca gene by a single loxP site. We compared the number of
dopaminergic neurons in the SNpc of this line, previously studied B6(Cg)-Sncatm1Rosl/J line and wild type littermate
mice. A similar decrease was observed in both knockout lines when compared with wild type mice. In a recently
published study we revealed no loss of dopaminergic neurons following conditional inactivation of the Snca gene
in neurons of adult mice. Taken together, these results strongly suggest that alpha-synuclein is required for efficient
survival or maturation of dopaminergic neurons in the developing SNpc but is dispensable for survival of mature
SNpc dopaminergic neurons.
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Background
Gain-of-function of alpha-synuclein has been strongly
linked to aetiology and pathogenesis of Parkinson’s and
several other neurodegenerative diseases (recent ad-
vances and perspectives are summarised in Ref [1]).
However, despite a growing body of evidence that sug-
gests its involvement in many important molecular pro-
cesses in healthy neurons, predominantly in presynaptic
terminals (for recent review see Ref [2]), it is not clear if
alpha-synuclein was required for survival and/or matur-
ation of neurons. Previous studies have demonstrated
that at least on the C57Bl6 genetic background, adult
mice lacking alpha-synuclein as the result of a naturally
occurred mutation or targeted inactivation of the
encoded gene have reduced complement of dopamin-
ergic neurons in their SNpc [3–7]. This deficiency be-
comes already evident in E12.5 embryonic brains and is
not progressive [3, 4, 7]. An uncertainty in interpretation
of these results is due to a possibility that some add-
itional genetic modifications present in both mouse lines
used in these studies, rather than the absent of alpha-
synuclein per se, could potentially cause partial loss of
dopaminergic neurons. A naturally occurred deletion in
the genome of Harlan UK C57Bl6 mice spans over ap-
proximately 350 kilobases, which causes the loss of func-
tion not only of alpha-synuclein encoded Snca, but also
of several other genes [8]. Mice of B6(Cg)-Sncatm1Rosl/J
line [9, 10] were produced by homologous recombin-
ation that resulted in a substitution of Snca exons by a
neo expression cassette, which presence dramatically ac-
tivate neuronal expression of a neighbouring Mmrn1
gene encoding multimerin 1, a protein whose function
in the nervous system is enigmatic (Additional file 1). To
avoid any disparity in the interpretation of data obtained in dif-
ferent mouse models and reaffirm that the loss of alpha-
synuclein is the primary cause of the deficit of dopaminergic
neurons in the substantia nigra of null mutant mice, we
employed a line of mice with a “clean knockout” of alpha-
synuclein. This B6(Cg)-Sncatm1.2Vlb/J line has recently been pro-
duced in our laboratory by Cre-driven recombination in the
genome of “floxed” and neo-free mice of B6(Cg)-Sncatm1.1Vlb/J
line followed by crosses with C57Bl6J mice to eliminate the
CMV-Cre transgenic cassette. Therefore, the only foreign DNA
sequence remaining in the genome of B6(Cg)-Sncatm1.2Vlb/J
mice is a single loxP site substituting the first coding exon of
Snca gene and some adjusted short intronic sequences. This
genetic modification completely abolishes production of alpha-
synuclein in homozygous animals [11].
Methods
Null mutant and wild type littermates were produced by
intercrossing of heterozygous animals and genotyped as
Fig. 1 Similar decrease in the number of dopaminergic neurons in SNpc of two alpha-synuclein knockout lines. a) The number of TH-positive
neurons in the SNpc of 4-month old wild type (WT), B6(Cg)- Sncatm1.2Vlb/J alpha-synuclein null (SncaVlb) and B6(Cg)-Sncatm1Rosl/J alpha-synuclein
null (SncaRosl) mice. Bar charts show mean ± SEM of numbers of stereologically counted neurons in SNpc of 8 animals for each genotype.
Statistical analysis using one-way ANOVA with Dunnett’s multiple comparisons test revealed significant difference between WT and each of null
mutant mouse groups (F (2, 45) = 4.854; p = 0.0123; **p = 0.0094; * p = 0.0451), whereas the difference between two null mutant mouse groups
was not significant (p = 0.5329). b) Representative images of brain sections through SNpc region immunostained with antibody against TH
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described elsewhere [9, 10]. Brains of 4-month old male
mice we fixed, histological sections prepared and immu-
nostained with antibody against tyrosine hydroxylase
(TH, mouse monoclonal antibody, clone TH-2, Sigma
diluted 1:1000); TH-positive neurons in the SNpc were
stereologically counted as described previously [3, 4, 6].
Results and discussion
Our morphometric analysis revealed that the total num-
ber of dopaminergic neurons in the SNpc of adult
B6(Cg)-Sncatm1Rosl/J mice was 18 ± 5.7% lower than in
the SNpc of wild type mice (Fig. 1, an additional Excel
file, Additional file 2, shows raw count data). This is
consistent with the previously reported data for this line
as well as for Harlan UK C57Bl6 alpha-synuclein null
mutant line [3–6]. Importantly, a similar reduction
(23 ± 7.0%) was found in the SNpc of a new “clean
knockout” B6(Cg)-Sncatm1.2Vlb/J line (Fig. 1). The latter
result clearly implies that dopaminergic neuron deficit
observed in studied alpha-synuclein null mutant mouse
lines is indeed caused by the lack of alpha-synuclein.
In another recent study we have demonstrated that in-
activation of Snca gene by the same genetic modification
as in B6(Cg)-Sncatm1.2Vlb/J line but induced by Cre re-
combination in neurons of adult or ageing B6(Cg)-
Sncatm1.1Vlb/J animals, caused complete depletion of
alpha-synuclein from the dorsal striatum, a brain region
where presynaptic terminals (i.e. sites of the predomin-
ant localisation of this protein) of the SNpc dopamin-
ergic neurons are located. However, such a late-onset
depletion did not lead to any loss of SNpc dopaminergic
neurons [12]. Taken together, results of our two studies
strongly suggest that alpha-synuclein is required for effi-
cient survival or maturation of dopaminergic neurons in
the developing SNpc but is dispensable for survival of
mature SNpc dopaminergic neurons. It is also cannot be
currently excluded that a certain population of develop-
ing dopaminergic neurons is particularly sensitive to the
absence of alpha-synuclein.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13041-020-00613-5.
Additional file 1 Expression levels of Mmrn1 mRNA in the cerebral
cortex of wild type and synuclein null mutant mice. Bar chart shows
relatives level of Mmrn1 mRNA in the cerebral cortex of the wild type
(WT), B6(Cg)- Sncatm1.2Vlb/J alpha-synuclein null (SncaVlb) and B6(Cg)-
Sncatm1Rosl/J alpha-synuclein null (SncaRosl) mice estimated by real-time
quantitative RT-PCR.
Additional file 2. Number of TH-positive neurons in SNpc of wild type
and synuclein null mutant mice. Raw data for neurons number counts in
the left and right SNpc of individual animals used in the study.
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